The susceptibility of human melanoma cells to infection with the Leningrad-16 vaccine strain of measles virus

Oncolytic viruses, including live attenuated measles virus (MV) vaccine strains, have recently been shown as promising therapeutic agents against human malignancies. In this study, the oncolytic potential of the attenuated vaccine strain Leningrad-16 (L-16) of MV was evaluated in a panel of human metastatic melanoma cell lines. The L-16 measles virus was shown to replicate within melanoma cells mediating direct cell killing of tumor cells, although all melanoma cell lines varied in regard to their ability to respond to L-16 MV infection, as revealed by the different pattern of the Interferon Stimulated Gene expression, cytokine release and mechanisms of cell death. Furthermore, the statistically significant L-16 measles virus related tumor growth inhibition was demonstrated in a melanoma xenograft model. Therefore, L-16 MV represents an appealing oncolytic platform for target delivery of therapeutic genes along with other attenuated measles virus strains. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Authors
Ammour Y.1 , Ryabaya O.2 , Shchetinina Y.1 , Prokofeva E.1 , Gavrilova M. 1 , Khochenkov D. 2, 3 , Vorobyev D.1, 4 , Faizuloev E.1 , Shohin I. 1, 5 , Zverev V.V.1, 4 , Svitich O.1, 4 , Nasedkina T.6
Journal
Publisher
MDPI AG
Number of issue
2
Language
English
Status
Published
Number
173
Volume
12
Year
2020
Organizations
  • 1 I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russian Federation
  • 2 N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, 115478, Russian Federation
  • 3 Medicinal Chemistry Center, Togliatti State University, Togliatti, 445020, Russian Federation
  • 4 I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Moscow, 119146, Russian Federation
  • 5 Institute of biochemical technology and nanotechnology, RUDN University, Moscow, 117198, Russian Federation
  • 6 Engelhardt Institute of Molecular Biology of, Russian Academy of Sciences, Moscow, 119991, Russian Federation
Keywords
Cancer immunotherapy; Measles virus; Oncolytic viruses
Share

Other records